Table 1.

Comparison of the performance of SARS-CoV-2 antibody assays and positivity rate across various scenarios.

Variable	Category	Total	Positivity rate (%)				P value
			Rapid IgG LFA test	Rapid IgG + IgM) LFA	Elecsys CLIA	In-house ELISA
Seroprevalence			47.1%	52.4%	46.3%	42.7%
Age	10_14	356	41	46.6	38.2	39.9	0.409
	15–18	647	48.5	54.2	49.6	42.9
	> 18	138	56.5	58.7	52.2	49.3
Sex	Female	647	46.5	52.5	45.4	45.3	0.045*
	Male	494	47.9	52.2	47.6	39.4
Comorbidity	No	1116	47.2	52.6	46.7	43.1	0.154
	Yes	18	33.2	33.3	27.8	22.2
	Do not know	7	71.4	71.4	42.9	28.6
Having contact with a confirmed case	No	1129	47	52.3	46.2	42.6	0.608
	Yes	12	58.3	58.3	58.3	50
Rapid IgG LFA test							0.000*
Rapid (IgG + IgM) LFA test							0.000*
Elecsys CLIA							0.000*
Overall prevalence( 95% , CI)						42.7%(39.8–45.6)

*Statically significant.